It is administered through subcutaneous route. The drug candidate is a protein which is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-beta receptor, activin ...
Evangelista's group added that ARBs "downregulate the TGF-beta-mediated signaling cascade ... Source Reference: Evangelista G "Angiotensin receptor blockers (ARBs) reduce the risk of developing ...
Beyond anti-inflammatory treatments, Enveda is developing candidates across multiple therapeutic areas, including small molecules for amyotrophic lateral sclerosis (ALS), Parkinson’s disease, fibrosis ...